📊 SLS Key Takeaways
Is SELLAS Life Sciences Group, Inc. (SLS) a Good Investment?
SELLAS is a pre-revenue pharmaceutical company facing fundamental business challenges with revenue collapsed to $79K and annual operating cash burn of $28.4M. While the strong balance sheet ($71.8M cash, zero debt) provides approximately 2.5 years of operational runway, the absence of meaningful revenue and massive operating losses indicate the company is in financial distress without clear catalysts for recovery.
Why Buy SELLAS Life Sciences Group, Inc. Stock? SLS Key Strengths
- Zero debt and no interest-bearing obligations eliminate financial leverage risk
- Cash position of $71.8M provides sufficient runway for continued operations through clinical development
- Excellent liquidity ratios (10.72x current and quick ratios) ensure near-term solvency
- Net loss improved 13% YoY, suggesting some operational cost discipline
SLS Stock Risks: SELLAS Life Sciences Group, Inc. Investment Risks
- Complete revenue collapse to $79K from prior periods indicates failed commercialization or discontinued products/partnerships
- Negative $28.4M operating cash flow with no revenue generation is structurally unsustainable
- Zero insider Form 4 filings in past 90 days reflects lack of management confidence in the business
- Company appears to be pre-revenue or failed-stage biotech with no demonstrated commercial viability
- Cash runway of 2.5 years at current burn rate creates critical timeline pressure without revenue recovery
Key Metrics to Watch
- Quarterly revenue trends and announcements of new product launches or licensing deals
- Operating cash burn trajectory and management guidance on path to profitability
- Clinical trial data releases and FDA approval decisions for pipeline drugs
- Insider stock transactions as early indicator of management confidence shifts
SELLAS Life Sciences Group, Inc. (SLS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.72x current ratio provides a solid financial cushion.
SLS Profit Margin, ROE & Profitability Analysis
SLS vs Healthcare Sector: How SELLAS Life Sciences Group, Inc. Compares
How SELLAS Life Sciences Group, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is SELLAS Life Sciences Group, Inc. Stock Overvalued? SLS Valuation Analysis 2026
Based on fundamental analysis, SELLAS Life Sciences Group, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
SELLAS Life Sciences Group, Inc. Balance Sheet: SLS Debt, Cash & Liquidity
SLS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: SELLAS Life Sciences Group, Inc.'s revenue has declined by 47% over the 5-year period, indicating business contraction. The most recent EPS of $-0.50 indicates the company is currently unprofitable.
SLS Revenue Growth, EPS Growth & YoY Performance
SLS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | N/A | -$7.0M | $-0.33 |
| Q2 2023 | N/A | -$8.4M | $-0.31 |
| Q1 2023 | N/A | -$11.1M | $-0.47 |
| Q3 2022 | N/A | -$7.0M | $-0.34 |
| Q2 2022 | N/A | -$4.6M | $-0.30 |
| Q1 2022 | $1.0M | -$2.4M | $-0.16 |
| Q3 2021 | N/A | -$4.5M | $-0.45 |
| Q2 2021 | N/A | -$4.4M | $-0.30 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
SELLAS Life Sciences Group, Inc. Dividends, Buybacks & Capital Allocation
SLS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for SELLAS Life Sciences Group, Inc. (CIK: 0001390478)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SLS
What is the AI rating for SLS?
SELLAS Life Sciences Group, Inc. (SLS) has an AI rating of SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SLS's key strengths?
Claude: Zero debt and no interest-bearing obligations eliminate financial leverage risk. Cash position of $71.8M provides sufficient runway for continued operations through clinical development.
What are the risks of investing in SLS?
Claude: Complete revenue collapse to $79K from prior periods indicates failed commercialization or discontinued products/partnerships. Negative $28.4M operating cash flow with no revenue generation is structurally unsustainable.
What is SLS's revenue and growth?
SELLAS Life Sciences Group, Inc. reported revenue of $79.0K.
Does SLS pay dividends?
SELLAS Life Sciences Group, Inc. does not currently pay dividends.
Where can I find SLS SEC filings?
Official SEC filings for SELLAS Life Sciences Group, Inc. (CIK: 0001390478) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SLS's EPS?
SELLAS Life Sciences Group, Inc. has a diluted EPS of $-0.25.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SLS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, SELLAS Life Sciences Group, Inc. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SLS stock overvalued or undervalued?
Valuation metrics for SLS: ROE of -37.9% (sector avg: 15%), net margin of -34,003.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SLS stock in 2026?
Our dual AI analysis gives SELLAS Life Sciences Group, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SLS's free cash flow?
SELLAS Life Sciences Group, Inc.'s operating cash flow is $-28.4M, with capital expenditures of $6.0K. FCF margin is -35,943.0%.
How does SLS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -34,003.8% (avg: 12%), ROE -37.9% (avg: 15%), current ratio 10.72 (avg: 2).